Senicapoc

Phase 2Small molecule

IIcagen

Senicapoc is one of 157 small molecule programs targeting Respiratory insufficiency. It is currently in Phase 2.

Indications

Total Trials

Active Trials

156

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory InsufficiencyActive, not recruiting

Atopic AsthmaActive, not recruiting

Interstitial Lung DiseaseActive, not recruiting

GlioblastomaActive, not recruiting

AsthmaActive, not recruiting

Sickle Cell DiseaseActive, not recruiting

Respiratory InsufficiencyPhase 2

Active, not recruiting

Atopic AsthmaPhase 2

Active, not recruiting

Interstitial Lung DiseasePhase 2

Active, not recruiting

GlioblastomaPhase 1

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Sickle Cell DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Veramyst

GSK

Preclinical

46 2

Xolair

Roche

Preclinical

25 3

Senicapoc

IIcagen

Phase 2

1 4

Cinqair

Teva

Preclinical

13 5

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 6

Asmanex

Novartis

Preclinical

5 7

Celexa

AbbVie

Preclinical

1 8

Spiriva

Boehringer Ingelheim

Preclinical

8 9

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 10

Arcoxia

Novartis

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Glioblastoma

NCT07284069

Phase 2Recruiting

Interstitial Lung Disease

NCT06714123

Q1 2029

Phase 2Not yet recruiting

Sickle Cell Disease

NCT07282210

Clinical

Trials by Indication[1]

Alzheimer's Disease1 trial

Senicapoc in Alzheimer's Disease

Recruiting·UUniversity of California, Davis·Phase 2·NCT04804241·55 enrolled

Respiratory insufficiency1 trial

Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency

Unknown status·UUniversity of Aarhus·Phase 2·NCT04594668·46 enrolled

Sickle Cell Disease1 trial

Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype

Not yet recruiting·BBiossil Inc.·Phase 2·NCT07282210·105 enrolled

Asthma1 trial

Study to Assess Safety and Efficacy of Oral Senicapoc Administration on Exercise-induced Asthma

Completed·IIcagen·Phase 2·NCT00861185·69 enrolled

Interstitial Lung Disease1 trial

Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease

Recruiting·VVejle Hospital·Phase 2·NCT06714123·140 enrolled

2 more indications

Atopic Asthma1 trial

Safety and Efficacy Study of Oral Senicapoc on Allergen Challenge in Atopic Asthmatic Subjects

Completed·IIcagen·Phase 2·NCT00861211·34 enrolled

Glioblastoma1 trial

Senicapoc and Perampanel for Newly Diagnosed Glioblastoma

Recruiting·—·Phase 1·NCT07284069·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Senicapoc. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Senicapoc compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Senicapoc. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Icagen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IIcagen

Senicapoc

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q1 2029

Trials by Indication[1]

Alzheimer's Disease1 trial

Respiratory insufficiency1 trial

Sickle Cell Disease1 trial

Asthma1 trial

Interstitial Lung Disease1 trial

Atopic Asthma1 trial

Glioblastoma1 trial

References

Drug Info

Quick Facts

Related News